Table 3.

Risk of moderate or severe shortness of breath among those reporting a positive COVID-19 test result.

	Reduced model	Full model
	(n = 788)	(n = 671)
	OR (95% CI)	OR (95% CI)
Age group
19–29	ref	ref
30–39	0.92 (0.57, 1.49)	0.87 (0.50, 1.49)
40–49	0.99 (0.61, 1.61)	0.93 (0.54, 1.60)
50–59	0.74 (0.42, 1.32)	0.71 (0.38, 1.34)
60+	0.64 (0.31, 1.30)	0.47 (0.21, 1.08)
Gender
Male	ref	ref
Female	1.35 (0.91, 2.02)	1.33 (0.85, 2.07)
Race
White	ref	ref
Black	1.02 (0.60, 1.73)	1.30 (0.73, 2.32)
Other/Multiracial	1.56 (0.96, 2.53)	1.28 (0.73, 2.25)
BMI category
Underweight or Normal weight (BMI < 25.0)	ref	ref
Overweight (25.0≤BMI < 30.0)	1.95 (1.18, 3.21)	1.89 (1.11, 3.22)
Obese (BMI≥30.0)	2.31 (1.46, 3.65)	2.30 (1.40, 3.78)
Ethnicity Hispanic
No	ref	ref
Yes	0.61 (0.37, 0.99)	0.67 (0.38, 1.16)
Education
4-year college degree	ref	ref
High school or less than high school	1.20 (0.73, 1.98)	1.59 (0.91, 2.80)
Some college or 2-year college degree	0.84 (0.54, 1.31)	0.83 (0.51, 1.35)
More than 4-year college degree	0.74 (0.45, 1.23)	0.70 (0.39, 1.25)
Comorbidities and medication usea
Nicotine addiction (smoker)		1.36 (0.78, 2.40)
Organ Transplant		3.07 (0.72, 13.09)
Cancer		0.27 (0.06, 1.22)
Cardiovascular disease		1.23 (0.54, 2.79)
Medication for hypertension		0.73 (0.44, 1.22)
Medication for diabetes		1.21 (0.66, 2.21)
Medication for autoimmune disease		0.86 (0.35, 2.10)
Medication for lung disease		3.68 (2.04, 6.62)

Notes: shortness of breath and severity assessed at baseline. Participants who reported shortness of breath, but did not report severity of the symptom were excluded from this analysis (n = 11).

^aReferent category includes participants who reported not having the condition of interest or not taking the medication of interest.